Edesa Biotech, Inc.

EDSA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.57 0.10 −3.75%
Market cap
$36.1M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
3/9
Altman Z
22.29
Beneish M
−4.36
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.67 16.82 4.76 2.76
Net Debt/EBITDA
4.42 5.20 2.34 1.88
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.30) (0.26) (0.24) (0.34)
Book value per Share
2.19 1.75 1.19 0.98
Free Cash Flow
(1.72) (2.09) (2.02) (3.08)
Other line items

Show all line items

Columns are period end dates